Skip to main content
SpringerLink
Log in

Prulifloxacin ECG Study

  • Correspondence
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Malik M. Does the prulifloxacin ECG study prove cardiac safety of the drug? Clin Drug Investig 2010; 30(1): 1–3

    Article  PubMed  CAS  Google Scholar 

  2. Rosignoli MT, Di Loreto G, Dionisio P. Effects of prulifloxacin on cardiac repolarization in healthy subjects: a randomized, crossover, double-blind versus placebo, moxifloxacin-controlled study. Clin Drug Investig 2010; 30(1): 5–14

    Article  PubMed  CAS  Google Scholar 

  3. Committee for Medicinal Products for Human Use (ICH Topic E14). Note for guidance on the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. CHMP/ICH/2/04 London, 25 May 2005 [online]. Available from URL: http://www.ema.europa.eu/pdfs/human/ich/000204en.pdf [Accessed 2010 Jan 15]

  4. Dixon R, Job S, Oliver R, et al. Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects. Br J Clin Pharmacol 2008; 66: 396–404

    Article  PubMed  CAS  Google Scholar 

  5. Lacroix P, Crumb WJ, Durando L, et al. Prulifloxacin: in vitro (HERG current) and in vivo (conscious dog) assessment of cardiac risk. Eur J Pharmacol 2003; 477(1): 69–72

    Article  PubMed  CAS  Google Scholar 

  6. Akita M, Shibazaki Y, Izumi M, et al. Comparative assessment of prulifloxacin, sparfloxacin, gatifloxacin and levofloxacin in the rabbit model of proarrhythmia. J Toxicol Sci 2004; 29(1): 63–71

    Article  PubMed  CAS  Google Scholar 

  7. Tsikouris JP, Peeters MJ, Cox CD, et al. Effects of three fluoroquinolones on QT analysis after standard treatment courses. Ann Noninvasive Electrocardiol 2006; 11(1): 52–6

    Article  PubMed  Google Scholar 

  8. Committee for Medicinal Products for Human Use (ICH Topic E14). Note for guidance on the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Questions and answers. EMEA/CHMP/ICH/310133/2008, June 2008 [online]. Available from URL: http://www.ema.europa.eu/pdfs/human/ich/31013308en.pdf [Accessed 2010 Jan 15]

  9. Salvi V, Karnad DR, Panicker GK, et al. Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development. Br J Pharmacol 2010; 159: 34–48

    Article  PubMed  Google Scholar 

  10. Shah RR, Morganroth J. Evaluating the QT-liability of a drug during its development. Pharm Med 2008; 22: 151–64

    Article  Google Scholar 

  11. Hollister AS, Montague TH. Statistical analysis plans for ECG data: controlling the intrinsic and extrinsic variability in QT data. In: Morganroth J, Gussak I, editors. Cardiac safety of noncardiac drugs. Totowa (NJ): Humana Press, 2005: 239–57

    Chapter  Google Scholar 

  12. Morganroth J, Ilson BE, Shaddinger BC, et al. Evaluation of vardenafil and sildenafil on cardiac repolarization. Am J Cardiol 2004; 93: 1378–83

    Article  PubMed  CAS  Google Scholar 

  13. Deasi M, Li L, Desta Z, et al. Variability of heart rate correction methods for the QT interval. Br J Clin Pharmacol 2002; 55: 511–7

    Article  Google Scholar 

  14. Malik M, Farbom P, Batchvarov V, et al. Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart 2002; 87: 220–8

    Article  PubMed  CAS  Google Scholar 

  15. Committee for Proprietary Medicinal Products (ICH Topic E3). Structure and content of clinical study reports. Step 5. Note for guidance on structure and content of clinical study reports. CPMP/ICH/137/95, July 1996 [online]. Available from URL: http://www.ema.europa.eu/pdfs/human/ich/013795en.pdf [Accessed 2010 Jan 15]

  16. Shah RR. Drugs, QTc interval prolongation and final ICH E14 guideline: an important milestone with challenges ahead. Drug Saf 2005; 28(11): 1009–28

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors are employees of Angelini Pharmaceuticals, ACRAF SpA, Rome, Italy.

Author information

Authors and Affiliations

  1. Headquarters Medical Department, Angelini Pharmaceuticals, ACRAF SpA, Rome, Italy

    Maria Teresa Rosignoli & Paolo Dionisio

Authors
  1. Maria Teresa Rosignoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paolo Dionisio
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rosignoli, M.T., Dionisio, P. Prulifloxacin ECG Study. Clin. Drug Investig. 30, 275–277 (2010). https://doi.org/10.2165/11311700-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11311700-000000000-00000

Keywords

Search

Navigation